Free Trial

Brookline Capital Management Analyst Recommendations & Stock Picks

This page lists the most recent publicly-reported stock recommendations and ratings issued by analysts at Brookline Capital Management. These ratings and price targets were collected from public media reports and are believed to be accurate, but cannot be verified with 100% certainty. MarketBeat and its parent company are in no way affiliated with or endorsed by Brookline Capital Management.

MarketBeat Brokerage Ranking:
Average 12-Month ROI of Buy Recommendations: Subscribe to Unlock


MarketRank™ evaluates a company based on dividend strength, earnings, valuation, analysts forecasts, and more.
Available with a MarketBeat All Access Subscription
MarketRank™Upgrade to All Access to use the All Ranks Filter
Media sentiment refers to the percentage of positive news stories versus negative news stories a company has received in the past week.
Available with a MarketBeat All Access Subscription
Media SentimentUpgrade to All Access to use the All Sentiments Filter
Analyst consensus is the average investment recommendation among Wall Street research analysts.
Available with a MarketBeat All Access Subscription
Analyst ConsensusUpgrade to All Access to use the All Ratings Filter
CompanyCurrent PriceReport DateAnalystActionRatingPrice TargetDetailsActions
Radiopharm Theranostics stock logo
RADX
Radiopharm Theranostics
$4.77
+3.0%
7/21/2025Kemp DolliverUpgradeStrong-Buy$18.00View details for Brookline Capital Management rating of Radiopharm Theranostics (NASDAQ:RADX) on 7/21/2025
Lisata Therapeutics stock logo
LSTA
Lisata Therapeutics
$2.66
+0.4%
7/15/2025Kemp DolliverBoost Price TargetBuy -> Buy$20.00 -> $32.00View details for Brookline Capital Management rating of Lisata Therapeutics (NASDAQ:LSTA) on 7/15/2025
Candel Therapeutics stock logo
CADL
Candel Therapeutics
$7.00
+0.6%
7/9/2025K. DolliverUpgradeStrong-BuyView details for Brookline Capital Management rating of Candel Therapeutics (NASDAQ:CADL) on 7/9/2025
TuHURA Biosciences stock logo
HURA
TuHURA Biosciences
$2.84
-3.7%
6/23/2025K. RajaUpgradeStrong-BuyView details for Brookline Capital Management rating of TuHURA Biosciences (NASDAQ:HURA) on 6/23/2025
BioVie stock logo
BIVI
BioVie
$7.55
-8.4%
3/18/2025T. BussianUpgradeStrong-BuyView details for Brookline Capital Management rating of BioVie (NASDAQ:BIVI) on 3/18/2025
CervoMed stock logo
CRVO
CervoMed
$8.05
-2.4%
3/11/2025T. BussianUpgradeHold -> Strong-BuyView details for Brookline Capital Management rating of CervoMed (NASDAQ:CRVO) on 3/11/2025
Perspective Therapeutics stock logo
CATX
Perspective Therapeutics
$4.15
-4.6%
3/10/2025K. DolliverUpgradeStrong-BuyView details for Brookline Capital Management rating of Perspective Therapeutics (NYSE:CATX) on 3/10/2025
I-Mab stock logo
IMAB
I-Mab
$2.12
+0.5%
2/27/2025K. RajaUpgradeStrong-BuyView details for Brookline Capital Management rating of I-Mab (NASDAQ:IMAB) on 2/27/2025
MARKER THERAPEUTICS stock logo
MRKR
MARKER THERAPEUTICS
$1.50
-6.3%
2/10/2025L. CannUpgradeStrong-BuyView details for Brookline Capital Management rating of MARKER THERAPEUTICS (NASDAQ:MRKR) on 2/10/2025
Cognition Therapeutics stock logo
CGTX
Cognition Therapeutics
$0.86
+7.0%
1/27/2025T. BussianUpgradeStrong-BuyView details for Brookline Capital Management rating of Cognition Therapeutics (NASDAQ:CGTX) on 1/27/2025
Medicus Pharma stock logo
MDCX
Medicus Pharma
$3.02
-1.0%
12/23/2024K. RajaUpgradeStrong-BuyView details for Brookline Capital Management rating of Medicus Pharma (NASDAQ:MDCX) on 12/23/2024
Exelixis stock logo
EXEL
Exelixis
$44.79
-1.3%
12/23/2024L. CannInitiated CoverageBuyView details for Brookline Capital Management rating of Exelixis (NASDAQ:EXEL) on 12/23/2024
Quince Therapeutics stock logo
QNCX
Quince Therapeutics
$1.86
12/18/2024K. RajaInitiated CoverageBuy$9.00View details for Brookline Capital Management rating of Quince Therapeutics (NASDAQ:QNCX) on 12/18/2024
CervoMed stock logo
CRVO
CervoMed
$8.05
-2.4%
12/10/2024T. BussianDowngradeStrong-Buy -> HoldView details for Brookline Capital Management rating of CervoMed (NASDAQ:CRVO) on 12/10/2024
Y-mAbs Therapeutics stock logo
YMAB
Y-mAbs Therapeutics
$4.84
+0.6%
12/4/2024K. DolliverUpgradeStrong-BuyView details for Brookline Capital Management rating of Y-mAbs Therapeutics (NASDAQ:YMAB) on 12/4/2024
Y-mAbs Therapeutics stock logo
YMAB
Y-mAbs Therapeutics
$4.84
+0.6%
12/5/2024-Initiated CoverageBuy$17.00View details for Brookline Capital Management rating of Y-mAbs Therapeutics (NASDAQ:YMAB) on 12/5/2024
Hyperion DeFi stock logo
HYPD
Hyperion DeFi
$8.17
-12.3%
11/15/2024K. DolliverReiterated RatingBuy -> HoldView details for Brookline Capital Management rating of Hyperion DeFi (NASDAQ:HYPD) on 11/15/2024
Envoy Medical stock logo
COCH
Envoy Medical
$1.63
+1.9%
10/14/2024T. BussianInitiated CoverageBuy$9.00View details for Brookline Capital Management rating of Envoy Medical (NASDAQ:COCH) on 10/14/2024
Verrica Pharmaceuticals stock logo
VRCA
Verrica Pharmaceuticals
$0.70
-0.7%
10/2/2024K. DolliverReiterated RatingBuy -> HoldView details for Brookline Capital Management rating of Verrica Pharmaceuticals (NASDAQ:VRCA) on 10/2/2024
OS Therapies stock logo
OSTX
OS Therapies
$1.73
-5.5%
8/22/2024K. RajaUpgradeStrong-BuyView details for Brookline Capital Management rating of OS Therapies (NYSE:OSTX) on 8/22/2024
iBio stock logo
IBIO
iBio
$0.74
-2.8%
7/22/2024K. DolliverInitiated CoverageBuy$3.60View details for Brookline Capital Management rating of iBio (NYSE:IBIO) on 7/22/2024
Unicycive Therapeutics stock logo
UNCY
Unicycive Therapeutics
$4.85
+5.2%
7/9/2024K. RajaUpgradeStrong-BuyView details for Brookline Capital Management rating of Unicycive Therapeutics (NASDAQ:UNCY) on 7/9/2024
CervoMed stock logo
CRVO
CervoMed
$8.05
-2.4%
7/8/2024T. BussianInitiated CoverageBuy$63.00View details for Brookline Capital Management rating of CervoMed (NASDAQ:CRVO) on 7/8/2024
SAB Biotherapeutics stock logo
SABS
SAB Biotherapeutics
$2.60
+4.4%
6/7/2024-Initiated CoverageBuy$8.00View details for Brookline Capital Management rating of SAB Biotherapeutics (NASDAQ:SABS) on 6/7/2024
Forte Biosciences stock logo
FBRX
Forte Biosciences
$10.75
+1.0%
5/30/2024-Initiated CoverageBuy$4.00View details for Brookline Capital Management rating of Forte Biosciences (NASDAQ:FBRX) on 5/30/2024
Dare Bioscience stock logo
DARE
Dare Bioscience
$2.63
-1.1%
5/15/2024K. DolliverUpgradeHold -> Buy$36.00View details for Brookline Capital Management rating of Dare Bioscience (NASDAQ:DARE) on 5/15/2024
Dare Bioscience stock logo
DARE
Dare Bioscience
$2.63
-1.1%
4/17/2024K. DolliverDowngradeBuy -> HoldView details for Brookline Capital Management rating of Dare Bioscience (NASDAQ:DARE) on 4/17/2024
Immunic stock logo
IMUX
Immunic
$1.07
+7.3%
4/5/2024T. BussianReiterated RatingBuy$10.00View details for Brookline Capital Management rating of Immunic (NASDAQ:IMUX) on 4/5/2024
Antibe Therapeutics stock logo
ATBPF
Antibe Therapeutics
$0.22
3/4/2024K. DolliverDowngradeBuy -> HoldView details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 3/4/2024
Annovis Bio stock logo
ANVS
Annovis Bio
$2.86
+7.5%
2/28/2024T. BussianDowngradeBuy -> Hold$9.00View details for Brookline Capital Management rating of Annovis Bio (NYSE:ANVS) on 2/28/2024
Oncobiologics stock logo
OTLK
Oncobiologics
$2.00
-3.8%
1/25/2024K. DolliverUpgradeHold -> Buy$31.40View details for Brookline Capital Management rating of Oncobiologics (NASDAQ:OTLK) on 1/25/2024
Cyclacel Pharmaceuticals stock logo
CYCC
Cyclacel Pharmaceuticals
$17.15
+22.5%
12/19/2023K. DolliverDowngradeBuy -> HoldView details for Brookline Capital Management rating of Cyclacel Pharmaceuticals (NASDAQ:CYCC) on 12/19/2023
Lantheus stock logo
LNTH
Lantheus
$70.93
-3.2%
11/30/2023-Initiated CoverageBuy$100.00View details for Brookline Capital Management rating of Lantheus (NASDAQ:LNTH) on 11/30/2023
Annovis Bio stock logo
ANVS
Annovis Bio
$2.86
+7.5%
11/10/2023T. BussianReiterated RatingBuy$35.00View details for Brookline Capital Management rating of Annovis Bio (NYSE:ANVS) on 11/10/2023
Genelux stock logo
GNLX
Genelux
$3.47
-3.6%
10/30/2023K. DolliverUpgradeHold -> BuyView details for Brookline Capital Management rating of Genelux (NASDAQ:GNLX) on 10/30/2023
Hyperion DeFi stock logo
HYPD
Hyperion DeFi
$8.17
-12.3%
10/17/2023-Initiated CoverageBuy$640.00View details for Brookline Capital Management rating of Hyperion DeFi (NASDAQ:HYPD) on 10/17/2023
Edesa Biotech stock logo
EDSA
Edesa Biotech
$2.40
+0.8%
10/12/2023-Reiterated RatingBuy -> Buy$57.00View details for Brookline Capital Management rating of Edesa Biotech (NASDAQ:EDSA) on 10/12/2023
Oncobiologics stock logo
OTLK
Oncobiologics
$2.00
-3.8%
8/30/2023K. DolliverDowngradeBuy -> HoldView details for Brookline Capital Management rating of Oncobiologics (NASDAQ:OTLK) on 8/30/2023
Antibe Therapeutics stock logo
ATBPF
Antibe Therapeutics
$0.22
8/14/2023K. DolliverReiterated RatingBuyView details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 8/14/2023
Dare Bioscience stock logo
DARE
Dare Bioscience
$2.63
-1.1%
2/14/2023K. DolliverReiterated RatingBuyView details for Brookline Capital Management rating of Dare Bioscience (NASDAQ:DARE) on 2/14/2023
The Trump Dump is starting; Get out of stocks now? (Ad)

The first 365 days of the Trump presidency… Will be the best time to get rich in American history.

If I’m right about this (like I was before) a modest $900 investment could grow to a life-changing a
electroCore stock logo
ECOR
electroCore
$7.47
+1.9%
1/12/2023K. DolliverReiterated RatingBuyView details for Brookline Capital Management rating of electroCore (NASDAQ:ECOR) on 1/12/2023
Vaxart stock logo
VXRT
Vaxart
$0.41
-2.9%
10/3/2022K. DolliverReiterated RatingBuyView details for Brookline Capital Management rating of Vaxart (NASDAQ:VXRT) on 10/3/2022
Oncobiologics stock logo
OTLK
Oncobiologics
$2.00
-3.8%
10/3/2022K. DolliverReiterated RatingBuyView details for Brookline Capital Management rating of Oncobiologics (NASDAQ:OTLK) on 10/3/2022
Monopar Therapeutics stock logo
MNPR
Monopar Therapeutics
$46.82
-0.1%
10/3/2022K. DolliverReiterated RatingBuyView details for Brookline Capital Management rating of Monopar Therapeutics (NASDAQ:MNPR) on 10/3/2022
Lisata Therapeutics stock logo
LSTA
Lisata Therapeutics
$2.66
+0.4%
10/3/2022K. DolliverReiterated RatingBuyView details for Brookline Capital Management rating of Lisata Therapeutics (NASDAQ:LSTA) on 10/3/2022
Edesa Biotech stock logo
EDSA
Edesa Biotech
$2.40
+0.8%
10/3/2022K. DolliverReiterated RatingBuyView details for Brookline Capital Management rating of Edesa Biotech (NASDAQ:EDSA) on 10/3/2022
Cyclacel Pharmaceuticals stock logo
CYCC
Cyclacel Pharmaceuticals
$17.15
+22.5%
10/3/2022K. DolliverReiterated RatingBuyView details for Brookline Capital Management rating of Cyclacel Pharmaceuticals (NASDAQ:CYCC) on 10/3/2022
Arcturus Therapeutics stock logo
ARCT
Arcturus Therapeutics
$14.95
-3.2%
8/10/2022K. RajaReiterated RatingBuyView details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 8/10/2022
Antibe Therapeutics stock logo
ATBPF
Antibe Therapeutics
$0.22
6/30/2022K. DolliverReiterated RatingBuyView details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 6/30/2022
Veru stock logo
VERU
Veru
$0.60
+2.7%
5/18/2022Kumaraguru RajaBoost Price TargetBuy -> Buy$29.00 -> $31.00View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 5/18/2022
Verrica Pharmaceuticals stock logo
VRCA
Verrica Pharmaceuticals
$0.70
-0.7%
3/10/2022K. DolliverReiterated RatingBuyView details for Brookline Capital Management rating of Verrica Pharmaceuticals (NASDAQ:VRCA) on 3/10/2022
Intellia Therapeutics stock logo
NTLA
Intellia Therapeutics
$12.78
-10.3%
3/7/2022L. CannUpgradeHold -> Buy$91.00View details for Brookline Capital Management rating of Intellia Therapeutics (NASDAQ:NTLA) on 3/7/2022
CRISPR Therapeutics stock logo
CRSP
CRISPR Therapeutics
$66.06
-3.1%
2/14/2022Leah RushReiterated RatingBuy$143.00View details for Brookline Capital Management rating of CRISPR Therapeutics (NASDAQ:CRSP) on 2/14/2022
Intellia Therapeutics stock logo
NTLA
Intellia Therapeutics
$12.78
-10.3%
2/14/2022Leah RushReiterated RatingBuyView details for Brookline Capital Management rating of Intellia Therapeutics (NASDAQ:NTLA) on 2/14/2022
Caribou Biosciences stock logo
CRBU
Caribou Biosciences
$2.37
-4.4%
2/14/2022L. CannReiterated RatingBuyView details for Brookline Capital Management rating of Caribou Biosciences (NASDAQ:CRBU) on 2/14/2022
BioCardia stock logo
BCDA
BioCardia
$2.31
-3.8%
2/3/2022K. RajaReiterated RatingBuyView details for Brookline Capital Management rating of BioCardia (NASDAQ:BCDA) on 2/3/2022
IceCure Medical stock logo
ICCM
IceCure Medical
$0.99
+1.5%
2/1/2022K. DolliverReiterated RatingBuyView details for Brookline Capital Management rating of IceCure Medical (NASDAQ:ICCM) on 2/1/2022
Dare Bioscience stock logo
DARE
Dare Bioscience
$2.63
-1.1%
1/19/2022K. RajaReiterated RatingBuyView details for Brookline Capital Management rating of Dare Bioscience (NASDAQ:DARE) on 1/19/2022
Kymera Therapeutics stock logo
KYMR
Kymera Therapeutics
$45.85
-1.2%
10/13/2021Leah Rush CannReiterated RatingBuy$80.00View details for Brookline Capital Management rating of Kymera Therapeutics (NASDAQ:KYMR) on 10/13/2021
Forte Biosciences stock logo
FBRX
Forte Biosciences
$10.75
+1.0%
9/3/2021K. RajaReiterated RatingHoldView details for Brookline Capital Management rating of Forte Biosciences (NASDAQ:FBRX) on 9/3/2021
Veru stock logo
VERU
Veru
$0.60
+2.7%
8/27/2021K. RajaReiterated RatingBuyView details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 8/27/2021
SCYNEXIS stock logo
SCYX
SCYNEXIS
$0.74
+0.5%
8/24/2021K. RajaReiterated RatingBuyView details for Brookline Capital Management rating of SCYNEXIS (NASDAQ:SCYX) on 8/24/2021
C4 Therapeutics stock logo
CCCC
C4 Therapeutics
$2.29
-5.4%
6/25/2021Leah Rush CannReiterated RatingBuyView details for Brookline Capital Management rating of C4 Therapeutics (NASDAQ:CCCC) on 6/25/2021
Antibe Therapeutics stock logo
ATBPF
Antibe Therapeutics
$0.22
6/3/2021K. DolliverReiterated RatingBuyView details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 6/3/2021
Monopar Therapeutics stock logo
MNPR
Monopar Therapeutics
$46.82
-0.1%
5/25/2021K. RajaReiterated RatingBuyView details for Brookline Capital Management rating of Monopar Therapeutics (NASDAQ:MNPR) on 5/25/2021
Bioceres Crop Solutions stock logo
BIOX
Bioceres Crop Solutions
$3.70
-0.8%
5/7/2021K. DolliverReiterated RatingBuyView details for Brookline Capital Management rating of Bioceres Crop Solutions (NASDAQ:BIOX) on 5/7/2021
Moderna stock logo
MRNA
Moderna
$34.01
-1.9%
2/26/2021-Boost Price TargetBuy$180.00 -> $205.00View details for Brookline Capital Management rating of Moderna (NASDAQ:MRNA) on 2/26/2021
Veru stock logo
VERU
Veru
$0.60
+2.7%
12/14/2020K. RajaBoost Price Target$13.00 -> $17.00View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 12/14/2020
electroCore stock logo
ECOR
electroCore
$7.47
+1.9%
10/23/2020S. YanchusInitiated CoverageBuy$75.00View details for Brookline Capital Management rating of electroCore (NASDAQ:ECOR) on 10/23/2020
Forte Biosciences stock logo
FBRX
Forte Biosciences
$10.75
+1.0%
8/28/2020K. RajaInitiated CoverageBuy$90.00View details for Brookline Capital Management rating of Forte Biosciences (NASDAQ:FBRX) on 8/28/2020
Kura Oncology stock logo
KURA
Kura Oncology
$6.47
+0.5%
8/16/2020L. CannReiterated RatingBuyView details for Brookline Capital Management rating of Kura Oncology (NASDAQ:KURA) on 8/16/2020
Veru stock logo
VERU
Veru
$0.60
+2.7%
8/14/2020K. RajaReiterated RatingBuyView details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 8/14/2020
Arcturus Therapeutics stock logo
ARCT
Arcturus Therapeutics
$14.95
-3.2%
8/11/2020K. RajaReiterated RatingBuyView details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 8/11/2020
Moderna stock logo
MRNA
Moderna
$34.01
-1.9%
7/13/2020L. CannReiterated RatingBuy$95.00View details for Brookline Capital Management rating of Moderna (NASDAQ:MRNA) on 7/13/2020
Assertio stock logo
ASRT
Assertio
$0.75
-2.7%
6/3/2020-Initiated CoverageBuy$3.50View details for Brookline Capital Management rating of Assertio (NASDAQ:ASRT) on 6/3/2020
Cyclacel Pharmaceuticals stock logo
CYCC
Cyclacel Pharmaceuticals
$17.15
+22.5%
5/19/2020K. RajaInitiated CoverageBuy$79,200.00View details for Brookline Capital Management rating of Cyclacel Pharmaceuticals (NASDAQ:CYCC) on 5/19/2020
Oncobiologics stock logo
OTLK
Oncobiologics
$2.00
-3.8%
5/5/2020K. RajaInitiated CoverageBuyView details for Brookline Capital Management rating of Oncobiologics (NASDAQ:OTLK) on 5/5/2020
Dare Bioscience stock logo
DARE
Dare Bioscience
$2.63
-1.1%
4/28/2020S. YanchusInitiated CoverageBuy$90.00View details for Brookline Capital Management rating of Dare Bioscience (NASDAQ:DARE) on 4/28/2020
Edesa Biotech stock logo
EDSA
Edesa Biotech
$2.40
+0.8%
3/30/2020K. RajaInitiated CoverageBuy$70.00View details for Brookline Capital Management rating of Edesa Biotech (NASDAQ:EDSA) on 3/30/2020
ClearPoint Neuro stock logo
CLPT
ClearPoint Neuro
$11.28
-2.6%
3/11/2020S. YanchusReiterated RatingBuyView details for Brookline Capital Management rating of ClearPoint Neuro (NASDAQ:CLPT) on 3/11/2020
Armata Pharmaceuticals stock logo
ARMP
Armata Pharmaceuticals
$2.48
+3.3%
3/13/2020K. RajaReiterated RatingBuyView details for Brookline Capital Management rating of Armata Pharmaceuticals (NYSEAMERICAN:ARMP) on 3/13/2020
ClearPoint Neuro stock logo
CLPT
ClearPoint Neuro
$11.28
-2.6%
3/12/2020-Initiated CoverageBuy$15.00View details for Brookline Capital Management rating of ClearPoint Neuro (NASDAQ:CLPT) on 3/12/2020
Monopar Therapeutics stock logo
MNPR
Monopar Therapeutics
$46.82
-0.1%
2/19/2020K. RajaInitiated CoverageBuy$210.00View details for Brookline Capital Management rating of Monopar Therapeutics (NASDAQ:MNPR) on 2/19/2020
Bioceres Crop Solutions stock logo
BIOX
Bioceres Crop Solutions
$3.70
-0.8%
2/4/2020S. YanchusReiterated RatingBuyView details for Brookline Capital Management rating of Bioceres Crop Solutions (NASDAQ:BIOX) on 2/4/2020
BioCardia stock logo
BCDA
BioCardia
$2.31
-3.8%
11/26/2019K. RajaReiterated RatingBuyView details for Brookline Capital Management rating of BioCardia (NASDAQ:BCDA) on 11/26/2019
BioCardia stock logo
BCDA
BioCardia
$2.31
-3.8%
11/26/2019-Initiated CoverageBuy$330.00View details for Brookline Capital Management rating of BioCardia (NASDAQ:BCDA) on 11/26/2019
Medicenna Therapeutics stock logo
MDNA
Medicenna Therapeutics
C$0.83
-2.4%
11/19/2019-Reiterated RatingBuyC$4.00View details for Brookline Capital Management rating of Medicenna Therapeutics (TSE:MDNA) on 11/19/2019
SCYNEXIS stock logo
SCYX
SCYNEXIS
$0.74
+0.5%
8/19/2019K. RajaReiterated RatingBuyView details for Brookline Capital Management rating of SCYNEXIS (NASDAQ:SCYX) on 8/19/2019
Vaxart stock logo
VXRT
Vaxart
$0.41
-2.9%
8/15/2019K. RajaInitiated CoverageBuy$6.00View details for Brookline Capital Management rating of Vaxart (NASDAQ:VXRT) on 8/15/2019
Veru stock logo
VERU
Veru
$0.60
+2.7%
7/29/2019K. RajaInitiated CoverageBuy$12.00View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 7/29/2019
The Trump Dump is starting; Get out of stocks now? (Ad)

The first 365 days of the Trump presidency… Will be the best time to get rich in American history.

If I’m right about this (like I was before) a modest $900 investment could grow to a life-changing a
Cellectar Biosciences stock logo
CLRB
Cellectar Biosciences
$5.35
-4.3%
7/29/2019K. RajaInitiated CoverageBuy$1,800.00 -> $1,800.00View details for Brookline Capital Management rating of Cellectar Biosciences (NASDAQ:CLRB) on 7/29/2019
Arcturus Therapeutics stock logo
ARCT
Arcturus Therapeutics
$14.95
-3.2%
7/24/2019K. RajaReiterated RatingBuyView details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 7/24/2019
SCYNEXIS stock logo
SCYX
SCYNEXIS
$0.74
+0.5%
1/4/2019K. RajaReiterated RatingBuyView details for Brookline Capital Management rating of SCYNEXIS (NASDAQ:SCYX) on 1/4/2019
Cellectar Biosciences stock logo
CLRB
Cellectar Biosciences
$5.35
-4.3%
11/20/2018K. RajaReiterated RatingBuyView details for Brookline Capital Management rating of Cellectar Biosciences (NASDAQ:CLRB) on 11/20/2018
Arcturus Therapeutics stock logo
ARCT
Arcturus Therapeutics
$14.95
-3.2%
9/27/2018K. RajaReiterated RatingBuyView details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 9/27/2018
Tonix Pharmaceuticals stock logo
TNXP
Tonix Pharmaceuticals
$44.72
-1.8%
7/27/2018K. RajaDowngradeBuy -> HoldView details for Brookline Capital Management rating of Tonix Pharmaceuticals (NASDAQ:TNXP) on 7/27/2018
Tonix Pharmaceuticals stock logo
TNXP
Tonix Pharmaceuticals
$44.72
-1.8%
5/1/2018K. RajaReiterated RatingBuyView details for Brookline Capital Management rating of Tonix Pharmaceuticals (NASDAQ:TNXP) on 5/1/2018

MarketBeat Community Rating for Brookline Capital Management

Community Ranking:  2.6 out of 5 (
2.6 of 5 stars)
Outperform Votes:  49,780 (Vote Outperform)
Underperform Votes:  45,209 (Vote Underperform)
Total Votes:  94,989
MarketBeat's community ratings are surveys of what our community members think about Brookline Capital Management and other research firms. Vote "Outperform" if you believe Brookline Capital Management's recommendations will outperform the S&P 500 over the long term. Vote "Underperform" if you believe Brookline Capital Management's recommendations will underperform the S&P 500 over the long term. You may vote once every thirty days.